醫(yī)療特長(zhǎng)：
1997年中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系畢業(yè),，直接留校后在中山一院歷任住院醫(yī)師，主治醫(yī)師,，副主任醫(yī)師,。獲腫瘤學(xué)碩士學(xué)位，長(zhǎng)期工作在醫(yī)療,、教學(xué),、科研第一線(xiàn)，積累了豐富的腫瘤診治臨床經(jīng)驗(yàn),。
擅長(zhǎng)常見(jiàn)腫瘤的診斷以及化療,、靶向治療、生物免疫治療等腫瘤內(nèi)科治療，熟悉肺癌,、乳腺癌,、胃癌,、結(jié)直腸癌,、膽管癌、胰腺癌,、前列腺癌,、食管癌、肝癌,、黑色素瘤,、軟組織肉瘤及淋巴瘤等全身各部位惡性腫瘤的全面病情評(píng)估、最新進(jìn)展與綜合治療,，對(duì)晚期惡性腫瘤病人以姑息止痛治療,、營(yíng)養(yǎng)支持治療為主的綜合治療有豐富的經(jīng)驗(yàn)。尤其對(duì)各種腫瘤并發(fā)癥處理,，減輕化療毒副反應(yīng)等方面有獨(dú)特經(jīng)驗(yàn),。
研究方向：
全身各部位惡性腫瘤的根治性化療、新輔助化療,、輔助化療,、同期化療放療、化療聯(lián)合靶向治療,、化療聯(lián)合生物細(xì)胞免疫治療以及晚期腫瘤的姑息治療,、靶向治療、免疫治療,。尤其是肺癌,、乳腺癌、胃腸道惡性腫瘤的綜合治療,。
主要教育和工作經(jīng)歷：
1992.9—1997.6中山醫(yī)科大學(xué)臨床醫(yī)學(xué)系本科
2009.9—2012.6中山大學(xué)腫瘤學(xué)碩士
1997.7—2002.6中山大學(xué)附屬第一醫(yī)院住院醫(yī)師
2002.6—2015.12中山大學(xué)附屬第一醫(yī)院主治醫(yī)師
2016.1至今中山大學(xué)附屬第一醫(yī)院副主任醫(yī)師
社會(huì)兼職：
廣東省抗癌協(xié)會(huì)癌癥康復(fù)與姑息治療專(zhuān)業(yè)委員會(huì) 青年委員
廣東省健康管理學(xué)會(huì)腫瘤防治專(zhuān)業(yè)委員會(huì) 委員
廣州抗癌協(xié)會(huì)胃癌專(zhuān)業(yè)委員會(huì) 委員
論著：
A：第一作者/共同第一/通訊作者
1) Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: A meta-analysis. Gene, 2013, Oct 10;528(2):335-42. (IF= 2.138) 第一作者/通訊作者
2) XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis. Tumour Biol, 2014 Jan;35(1):447-53. (IF= 3.611) 第一作者/通訊作者
3) Xeroderma pigmentosum complementation group D (XPD)gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol, 2014 Apr;35(4):3905-15. (IF= 3.611)
4) A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget, 2015 Apr 20;6(11):8676-86. (IF= 6.359)
5) Osterix transcriptional factor is involved in the metastasis of human breast cancers. Oncol Lett, 2015 Sep;10(3): 1870-1874. (IF= 1.554)
6) Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: A meta-analysis. J BUON, 2014 Dec;19(4): 917-24. (IF= 0.741)通訊作者
7) Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol, 2014 Nov;2(6):1047-1054.
8) The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic Nasopharyngeal Carcinoma. PLoS One, 2014 Nov 13;9(11):e112581. (IF= 3.234)
9) Prediction of occult cervical lymph node metastasis in clinically negative supraglottic squamous cell carcinoma. Head Neck Oncol, 2012, Oct 27;4(3):69.
10) PSCA s2294008 C>T and rs2976392 G>A polymorphisms contribute to cancer susceptibility: evidence from published studies.Genes Cancer, 2015 May;6(5-6):254-64.
11) β-葡萄糖神經(jīng)酰胺與HBsAg-DC瘤苗協(xié)同治療肝癌的實(shí)驗(yàn)研究 [J/CD]. 中華普通外科學(xué)文獻(xiàn): 電子版, 2013, 7(4):298-302.
12) 奧曲肽預(yù)防伊立替康引起的遲發(fā)性腹瀉的臨床研究. 新醫(yī)學(xué), 2012, 43(3):155-158.
B：其他排名論著
13) Zhou H, Wei J, Dai Q, Wang L, Luo J, Cheang T, Wang S. CaCO3/CaIP6 composite nanoparticles effectively deliver AKT1 small interfering RNAto inhibit human breast cancer growth. Int J Nanomedicine, 2015 Jul 1;10:4255-66. (IF= 4.383)
14) Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm, 2014 Oct 20;474(1-2):112-22. (IF= 3.65)
15) Chen C, Sun P, Rong J, Weng HW, Dai QS, Ye S. Short Course Radiation in the Treatment of Localized Rectal Cancer: A Systematic Review and Meta-Analysis. Sci Rep. 2015 Jun 9;5:10953. (IF= 5.578)
16) Long J, Zhou B, Li H, Dai Q, Zhang B, Xing S, Zeng Z, Chen W, Yang J. Improvement of HbsAg Gene-Modified Dendritic Cell-Based Vaccine Efficacy by Optimizing Immunization Method or the Application of β-glucosylceramide. Immunol Invest. 2013 Jan 16;42(2):137-55. (IF= 1.991)
17) Long JT, Cheang TY, Zhuo SY, Zeng RF, Dai QS, Li HP, Fang S. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnology. 2014 Sep 30;12(1):37. (IF= 4.115)
18) 王天寶, 戴強(qiáng)生, 尉秀清, 林維浩, 石漢平,董文廣. CXCR4 RNA干擾序列篩選及對(duì)結(jié)腸癌細(xì)胞SW480生長(zhǎng)的影響[J/CD]. 中華普通外科學(xué)文獻(xiàn): 電子版, 2012, 6(5):394-399.
專(zhuān)著：
廣東科學(xué)技術(shù)出版社《實(shí)用胃腸惡性腫瘤診療學(xué)》副主編
